Outliers and Patients with Adverse Drug Reactions I. Ralph Edwards Editorial 19 October 2012 Pages: 623 - 624
Do Nanomedicines Require Novel Safety Assessments to Ensure their Safety for Long-Term Human Use? Peter HoetBarbara LegiestBenoit Nemery Current Opinion 19 October 2012 Pages: 625 - 636
Serenoa repens (Saw Palmetto) Taofikat B. AgbabiakaMax H. PittlerEdzard Ernst Review Article 19 October 2012 Pages: 637 - 647
Amyotrophic Lateral Sclerosis-Like Conditions in Possible Association with Cholesterol-Lowering Drugs Beatrice A. GolombEdwin K. KwonMarcella A. Evans Short Communication 19 October 2012 Pages: 649 - 661
Application of the Bow-Tie Model in Medication Safety Risk Analysis Peter C. WierengaLoraine Lie-A-HuenSusanne M. Smorenburg Original Research Article 19 October 2012 Pages: 663 - 673
Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Fei-Yuan HsiaoWeng-Foung HuangYi-Wen Tsai Original Research Article 19 October 2012 Pages: 675 - 690
Remedies Containing Asteraceae Extracts Elke JeschkeThomas OstermannHarald Matthes Original Research Article 19 October 2012 Pages: 691 - 706
Comment on “Drug-Induced Thrombocytopenia: An Updated Systematic Review” Bart L. De KeulenaerChan Y. Cheah Correspondence 19 October 2012 Pages: 707 - 707